exigencies have been well-described. [4] [5] [6] In addition, A1C reflects only mean glucose levels and does not provide information about the frequency, duration and severity of hypoglycemia and hyperglycemia, the time in range, and glucose variability. These metrics are critical to the understanding of short-term glycemic control and may have implications for long-term complications.
The ability of continuous glucose monitoring (CGM) to collect key metrics of glycemic control (including mean glucose levels) allows us to go beyond A1C in understanding most, if not all, the important variables comprising glycemic control. By utilizing CGM-derived data, we can develop glucose-centric, composite metrics that eliminate the chore of having to individually compare individual aspects of glycemic control. Indeed, there has been a recent interest in providing a more comprehensive description of glycemic control that includes hypoglycemia and time in range as a supplement to A1C as a performance metric and the basis for regulatory approval. [7] [8] [9] The European Medicines Agency encourages the use of CGM in the determination of overnight profiles, postprandial hyperglycemia and hypoglycemia rates in clinical trials, 10 although it is not clear to what degree these data contribute to regulatory approval and labeling.
There have been several attempts to develop and display CGM-based composite metrics. Such metrics can be grouped into those that are purely visual, [11] [12] [13] purely numeric, 14, 15 and a combination of visual and numeric. 16 We have developed a new composite metric, the CGM-derived Glucose Pentagon (Comprehensive Glucose Pentagon or CGP), that includes all the key metrics of glycemic control: mean sensor glucose, glucose variability, severity of hypo-and hyperglycemia, and time out of range (the inverse of time in range), while eliminating A1C as an integral component. We have reanalyzed data from the Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) trial 17 and the Automation to Simulate Pancreatic Insulin Response (ASPIRE) In-Home trial 18 to validate this approach and determine if additional insights beyond those initially reported in those studies can be obtained using the CGP. Based on these analyses, we believe that the CGP can also be used to better evaluate glycemic control with CGM-derived data in individual subjects. In clinical practice, the CGP should be able to compare an individual patient's overall glycemic control in short time periods, for example, daily, weekly, and monthly, which is not possible with A1C.
Methods
The five axes of CGP are shown in Figure 1 . Compared to the original Glucose Pentagon model, 16 the A1C axis has been eliminated and the metric of glycemic variability is now % coefficient of variation (%CV) instead of standard deviation (SD). There are three new axes: (1) time out of range (ToR)-the reciprocal of time in range (so expressed to permit increasing/decreasing pentagon area as TIR worsens/ improves) which is defined as: 1440 min -time in range min (TIR min ); (2) the intensity of hyperglycemia or IntHyper (in place of AUC >160 mg/dl and time >160 mg/dl) which is expressed as AUC Time + , since there was no previous axis reflecting hypoglycemia . Only the mean glucose level is retained from the original Glucose Pentagon.
The approach to scaling of the mean glucose and glycemic variability axes have been previously described in detail. 16 Briefly, the mean glucose scale-transformed from the relationship of A1C to mean glucose by the formula Average Glucose (mg/dl) = 28.7 × A1c − 46.7 6 -is weighted to reflect the risk of developing microvascular complications as originally reported in the DCCT study. Since there were different curvilinear relationships between the risk of complications and A1C, we have used the average risk of all the complications as they relate to A1C. No similar relationship of glycemic variability (either SD or %CV) to long-term complications exists so we have used a linear scale based on the published relationship of oxidative stress and glycemic variability. 19, 20 For the hypoglycemia and hyperglycemia axes, the CGP displays the intensity of hypoglycemia (IntHypo) and intensity of hyperglycemia (IntHyper) which are the lengths of the vector of two standard metrics of hypoglycemia and hyperglycemia-area under the curve (AUC) ≤70 mg/dL and time/day Compared to the original Glucose Pentagon model, the new axes include the intensity of hyperglycemia (in place of AUC >160 mg/dl and time >160 mg/dl), intensity of hypoglycemia (no previous hypoglycemia axis), time out of range (1440 min -time in range) (in place of A1C because of the known discrepancies between A1C and mean glucose. 6 Mean glucose remains as one of the axes. The green pentagon is the area of an average person without diabetes and has an area = 466 mm 2 . The area of the CGP is calculated by summing the areas of five 72° triangles according to the following: The length of all axes is 76 mm. The green pentagon has an area of 466 mm 2 and represents the glycemic status of someone without diabetes. Based on the limited number of studies that have done CGM in nondiabetic subjects, we chose the following values for the normal glucose pentagon: Mean sensor glucose = 90 mg/dl, SD = 15 mg/dl resulting in a CV 16.7%, IntHypo = 0, IntHyper = 0, ToR = 0. 22, 23 By setting that area to equal 1, the area of any CGM-derived set of data permits a direct comparison of the glycemic control of an individual person or group of persons with diabetes to those without diabetes and is postulated to represent a relative risk of a combination of hypoglycemia and long-term complications on a scale of 1 to 5, called prognostic glycemic risk (PGR) parameter. We have arbitrarily assigned descriptions of risk to the PGR as follows: If the PGR ≤ 2.0, the patient has a very low risk for diabetes short-and/or long-term complications; for 2.0 < PGR ≤ 3.0 the risk is low; for 3.0 < PGR ≤ 4.0 the risk is moderate; 4.0 < PGR ≤ 4.5 high and > 4.5 extremely high.
We used data from two studies using CGM, the STAR 3 and ASPIRE In-Home trials, to determine how to scale the axes. The STAR 3 and ASPIRE In-Home trials have been previously described in detail. 17, 18 Briefly, in the STAR 3 trial, 495 adults and children were randomized to therapy with multiple daily injections (MDI) and glucose monitoring by fingerstick-obtained blood samples or continuous subcutaneous insulin infusion with glucose monitoring by CGM or sensor-augmented pumping (SAP) for 1 year. The A1C (the primary outcome metric) improved by 0.8% in the SAP group and by 0.2% in the MDI group (P < .0001). The rate of severe hypoglycemia (needing assistance and a documented BG value of <50 mg/dL) was not significantly different between the two groups. CGM was performed on all subjects at baseline, 6 and 12 months. The AUC <50 mg/dL and <70 mg/dL were not different between the groups, but the AUC >180 mg/dL and >250 mg/dL were significantly improved in the SAP group compared to MDI (P < .0001). The ASPIRE In-Home trial randomized 247 adolescent and adult subjects to sensor-augmented pump without a threshold suspend feature (SAP-TS) or sensor-integrated pump with a threshold suspend feature (SIP+TS) for 3 months. Those with the SIP+TS had a reduction in AUC of nocturnal hypoglycemia (the primary outcome metric) by 37.5% compared to SAP alone (P < .001) and a reduction in the number of sensor glucose values <50 mg/dL, <60 mg/dL, and <70mg/dL at night and also day plus night (P < .001). There was no significant change in the A1C in either group. Thus, the STAR 3 and ASPIRE In-Home trials provide an opportunity to compare composite outcomes in studies that differ both in types of interventions (SAP vs MDI and SAP-TS vs SIP+TS), as well as in the types of outcomes (improvement in A1C without a reduction in hypoglycemia in STAR 3 and a reduction in hypoglycemia without a change in A1C in ASPIRE In-Home).
Given the normal distribution of patient values, we used paired t-tests to compare the changes between baseline and end of study for both STAR 3 and ASPIRE In-Home studies.
Results
The CGM-derived data from the STAR 3 and ASPIRE In-Home trials are shown in Tables 1 and 2 . The standard glucose metrics of the SAP and MDI cohorts in the STAR 3 trial demonstrate that those subjects had much less well-controlled diabetes at baseline than those in the ASPIRE In-Home trial. For example, mean glucose was 184 mg/dL and 185 mg/dL versus 147 mg/dL and 147 mg/dL, respectively and A1C was 8.3% and 8.3% versus 7.3% and 7.2%, respectively at baseline. The glucose pentagon area and most of its components-time out of range, intensity of hyperglycemia, intensity of hypoglycemia, and CV-were also worse in STAR 3 subjects compared with those subjects in the ASPIRE In-Home trial. Conversely, the intensity of hypoglycemia, at baseline, was worse in the both groups in the ASPIRE In-Home trial compared with both STAR 3 groups. The PGR at baseline in each trial is: is 2.41 (SAP group) and 2.72 (MDI group) in the STAR 3 trial and 2.27 (SIP+TS) and 2.42 (SAP-TS) in the ASPIRE In-Home trial. Table 3 shows the percentage differences in the glucose pentagon area between the baseline and end of study for both the STAR 3 and ASPIRE In-Home studies.
In the STAR 3 trial, the interventions demonstrated improved overall glycemic control as exemplified by the reduction in the CGP areas. In the ASPIRE In-Home trial, the CGP area and therefore the PGR did not significantly change. However, the reason(s) for the resultant CGP areas in the intervention versus control groups were different in each study. In the STAR 3 trial, the reduction of the CGP area in the SAP cohort resulted from a significantly greater improvement in three metrics: mean glucose, ToR and IntHypo, compared to the MDI group. In the ASPIRE In-Home trial, the SIP+TS cohort had a significant decrease in the IntHypo, but this was offset by an increase in the IntHyper. The PGR was already low and not significantly changed in either group (Figures 2 and 3) . Examples of an individual from each study's intervention arm is shown in Figure 4 (STAR 3) and Figure 5 (ASPIRE In-Home). The examples from individual patients illustrate the capability of the CGP to clearly illustrate what elements of glycemic control were affected by each intervention and demonstrate the trade-offs that sometimes exist between short-term and long-term risk reduction. Because the data analyzed in this study represent that of a large patient population, it is not surprising that there is a good correlation between the mean glucose and the intensity of hyperglycemia and the ToR in these studies (r = .75-.85). However, for an individual patient, the correlation may be significantly lower especially in a patient who has a high IntHypo and/or high IntHyper.
Discussion
The CGP extends the novel approach of the original Glucose Pentagon in several ways. First, it establishes a composite metric that is entirely glucose-centric by eliminating the need for a laboratory derived metric, that is, A1C. This accomplishes several important goals. It circumvents the issue that an A1C may represent widely different mean glucose levels between individuals. 6, 24 For example, an A1C of 8% can reflect a mean glucose between 120 mg/dL and 200 mg/dL. These discrepancies are thought to be due to genetic and/or clinical differences in glycation rates, red cell survival, and ethnicity among others. Second, since the CGP can be calculated at frequent intervals it permits a short-term analysis of glycemic control, which A1C cannot provide because it is slow to change. By incorporating a program that calculates the CGP into CGM software, it could be accessed by the patient and/or health care provider on a daily, weekly or monthly basis. Third, the CGP can both numerically and pictorially identify the component(s) of glycemic control that are most in need of improvement by either a review of the analytical data that comprises the CGP or by visual review. Fourth, it incorporates two key metrics, time in range (expressed in the CGP as its reciprocal, ToR) and intensity of hypoglycemia, which are important correlates of quality of life. At the August 2016 Food and Drug Administration Outcomes Measures Beyond Hemoglobin A1C workshop, data from a 3,455-patient online survey of people with both type 1 and type 2 diabetes conducted by the diaTribe Foundation and dQ&A showed that time in range ranked first in what was most impactful in the daily lives of those individuals regardless of therapy. 25 In addition, the DAWN2 found that 56% of persons living with diabetes felt very worried about the risk of hypoglycemia and 39% reported that taking diabetes medications interfered with their quality of life. 26 The use of IntHypo and IntHyper goes beyond the standard metrics of AUC, %Hypo and %Hyper. The AUC represents the integral over glucose values over the time. If the glucose level was constant and the AUC is known, the duration of hypo-or hyperglycemia can be derived. However, glucose levels constantly vary. Under those circumstances, there are situations where equivalent AUC's have very different durations ( Figure 6 ). Thus, the intensity of hyper-or hypoglycemia are calculated as the length of the vector between AUC and time using the formula AUC Time 2 2 + . Finally, the CGP incorporates several parameters that have not been previously considered in composite metrics. The first is the intensity of hypoglycemia, which is not the product of duration and AUC, but rather the vector of these two metrics as described in the companion paper. 27 The inclusion of duration in both of the intensity terms provides additional weighting of this important metric, which is generally expressed as simple individual terms of frequency, duration, and/or AUC. There have been numerous ways to define hypoglycemia both clinically and numerically and but 29 there are revised definitions of clinical and biochemical hypoglycemia However, the biochemical definitions are unidimensional when obtained by blood glucose testing and thus provide no information about the depth or duration of hypoglycemia over time. Even when using CGM, the American Diabetes Association and the International Hypoglycemia Study Group propose that a static measure of CGM-derived sensor glucose level of 54 mg/dL for 20 minutes defines biochemical hypoglycemia. 28, 29 The intensity of hyperglycemia is the second new parameter. An approach like that used to develop the intensity of hypoglycemia was used to calculate it. Finally, we use ToR (the inverse of time in range) for one of the axes. Expressing it as ToR permits an improvement in glycemic control to be displayed as a reduction in the length of the axis and thus a reduction of the CGP area.
The CGP is still slightly weighted toward hyperglycemia because of the nonnormal distribution of glucose. However, we believe that log transformation of the data would make it difficult for the typical reader to understand such metrics. Investigators may choose to explore that option in the future in determining whether it correlates better with outcomes than the present composition of the CGP.
In developing the original Glucose Pentagon model, Thomas and colleagues included primarily metrics that reflected hyperglycemia, as these could be related to the microvascular outcomes results of the Diabetes Control and Complications trial. This permitted scaling of the axes in proportion to the exponential curves relating A1C and mean glucose to the risk of complications. They were cautious in their conclusions by suggesting that the clinical relevance of their model would have to be independently validated against future studies with the effects of an intervention on hard clinical outcomes. We also feel that the CGP approach needs validation in subsequent clinical trials to determine if the current approach to scaling is correct and to assess the utility of this approach in predicting short-and long-term clinical outcomes. Thomas and colleagues included the metric of glycemic variability (SD) assuming that it was linearly correlated to the risk of complication based on in vitro and limited in vivo studies on the relationship of glycemic variability and markers of oxidative stress. 16 In the CGP, we have changed from SD to %CV to accommodate the nonnormal distribution of glucose. In addition, CV, unlike SD, is independent of mean glucose. Including a glycemic variability axis is intended to reflect the importance of this metric in short-term control of diabetes. However, we recognize that there continues to be controversy over the relationship of glycemic variability to long-term microvascular complications. [30] [31] [32] Preclinical experiments have demonstrated that variable glucose levels significantly increase marker of oxidative stress in human umbilical endothelial cells as well as increase the production of VEGF by retinal epithelium. [33] [34] [35] Thus, ToR is less important than %CV in this model. While it will be logistically and financially unlikely that DCCT and UKPDS-like trials will be repeated, we would encourage the pharmaceutical industry to incorporate CGM into the cardiovascular outcomes trials that are now mandated by the Food and Drug Administration for all new diabetes drugs. These trials often include microvascular complications as well. This would permit a better understanding of how CGMderived, glucose-centric composite metrics affect clinical outcomes .
Based on the analyses presented herein, we believe that the CGP provides additional insights about the STAR 3 and ASPIRE In-Home trial that were either missing from and/or difficult to appreciate in the reports of those trials. In addition, this approach permits a straight forward comparison of cohorts in different trials as well as changes within the trials. In addition to its use in assessing the results of clinical trials, the CGP can provide a short-term clinical metric for use by both patients and their health care providers that supplements the A1C. Lipska and Krumholtz have recently questioned whether or not A1C or, indeed, any metric of glycemic control are the appropriate metrics for determining benefit in clinical trials. 5 Whether or not an approach which incorporates multiple metrics of glycemic control like the CGP may better predict outcomes must be determined by applying it to long-term clinical trials and to large databases which include data from insurance claims, electronic record information along with CGM data. This will allow refinement of the CGP that may include alternate metrics and/or different scaling based on such data. 
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